Impact of nano-selenium supplementation add-on sertraline on depressive symptoms and oxidative stress in patients with major depressive disorder: a triple-blind randomized controlled trial
- 7 October 2025
- journal article
- research article
- Published by Springer Nature in BioMetals
- Vol. 39 (1) , 119-131
Abstract
Major depressive disorder (MDD) is a prevalent psychiatric condition associated with increased oxidative stress, which may contribute to its pathophysiology. Elevated malondialdehyde (MDA) levels and reduced total antioxidant capacity (TAC) and glutathione peroxidase (GPX) activity have been observed in individuals with MDD. Nano-selenium, a novel formulation with enhanced bioavailability and antioxidant potency compared to conventional selenium, may help modulate these oxidative stress biomarkers. In this randomized, triple-blind, placebo-controlled trial, 50 adults newly diagnosed with MDD received either nano-selenium (55 µg/day) or placebo, both alongside sertraline (50 mg/day), over a 12-week period. A total of 42 participants (21 per group) completed the study. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HDRS), and serum levels of GPX, TAC, and MDA were assessed at baseline and post-intervention. Compared to placebo, nano-selenium significantly reduced depressive symptoms (mean change: −5.09 ± 4.94; P < 0.001) and increased TAC (mean change: 0.03 ± 0.04 mmol/L; P = 0.003) and GPX levels (median change: 9.56 U/L; IQR: −7.86 to 30.31; P = 0.044). While MDA levels decreased significantly in both groups, between-group differences were not statistically significant. These findings suggest that nano-selenium may serve as a safe and effective adjunctive therapy for reducing depressive symptoms and improving antioxidant status in MDD. However, the short duration and modest sample size of this study limit generalizability. Larger, multicenter trials with extended follow-up are recommended to confirm and expand upon these results. This study was approved by the Research Ethics Committee of Iran University of Medical Sciences (IR.IUMS.REC.1402.206; June 13, 2023) and registered with the Iranian Registry of Clinical Trials (IRCT20091114002709N62; July 29, 2023). Written informed consent was obtained from all participants. Graphical abstractKeywords
Funding Information
- Iran University of Medical Sciences (1402-2-2-26358)
This publication has 45 references indexed in Scilit:
- Optimal Serum Selenium Concentrations Are Associated with Lower Depressive Symptoms and Negative Mood among Young AdultsThe Journal of Nutrition, 2015
- Metalloproteomics: principles, challenges and applications to neurodegenerationFrontiers in Aging Neuroscience, 2013
- Selenium level and depressive symptoms in a rural elderly Chinese cohortBMC Psychiatry, 2012
- Effect of supplementation with selenium on postpartum depression: a randomized double-blind placebo-controlled trialThe Journal of Maternal-Fetal & Neonatal Medicine, 2010
- Effect of Micronutrient Supplementation on Mood in Nursing Home ResidentsGerontology, 2008
- Comparison of Two-Phase Treatment With Imipramine or Fluvoxamine, Both Followed by Lithium Addition, in Inpatients With Major Depressive DisorderAmerican Journal of Psychiatry, 2004
- Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitorsRedox Report, 2003
- Psychological Burden in the Era of Haart: Impact of Selenium TherapyThe International Journal of Psychiatry in Medicine, 2003
- Selenium Intake, Mood and Other Aspects of Psychological FunctioningNutritional Neuroscience, 2002
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960